AstraZeneca is buying Fusion Pharmaceuticals, a Canadian company specializing in radioconjugation cancer treatments, for $2.4 billion.
Petru Nicolaescu
Health
Unsplash.com
Always see our news on Google
The acquisition of Fusion Pharmaceuticals by AstraZeneca brings innovative new treatments to the company's portfolio. Radioconjugates developed by Fusion are an alternative to chemotherapy and radiotherapy, minimizing damage to healthy cells. The most advanced treatment, FPI-2265, is for patients with metastatic prostate cancer.
Latest News
22:49
Radu Miruță announces that USR and PNL are discussing an alliance for the 2028 local and parliamentary elections
22:25
Ilie Bolojan calls for the PNL to be rebuilt through truth, accountability and strong teams
22:02
Donald Trump promotes Stephen Miller to White House chief of staff
21:29
President of the Bavarian State Parliament backed for the German presidency / The nomination of the CSU politician could be confirmed on Monday
21:28
Sviatlana Tsikhanouskaya received the Prize for European Values in Timișoara and will donate the money to Belarusian culture
See more news
NEWS ON THE SAME TOPICS
IT&C knowledge
Novo collaborates with Anthropic to use artificial intelligence in the research and development of new medicines
International
An experimental cancer vaccine, developed by Moderna and Merck, has shown promising results in patients with melanoma.
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
